Status:
TERMINATED
"The Efficacy of Exparel Versus a Multidrug Cocktail in Soft Tissue Tumors"
Lead Sponsor:
Atlantic Health System
Conditions:
Musculoskeletal Diseases
Soft Tissue Mass
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The objective of this proposed project is to determine which local anesthetic is more efficacious for use in soft tissue tumors: Exparel (liposomal bupivacaine) or a cocktail of Ropivicaine, Epinepher...
Detailed Description
In recent years, there has been a substantial push to create a post-surgical protocol consisting of multimodal analgesia across multiple surgical subspecialties to decrease narcotic consumption and co...
Eligibility Criteria
Inclusion
- All primary soft tissue tumors
- Any adult patient (over 18 years old) with a soft tissue tumor confirmed with advanced imaging.
- Two different study groups will be examined:
- Those patients undergoing resection of their soft tissue tumor intraoperatively injected with Exparel
- Those patients undergoing resection of their soft tissue tumor intraoperatively injected with the cocktail.
- Those two groups will be further stratified by anatomic location; Upper vs lower extremity, size; tumors ≥ 10cm, tumors ≥ 5cm, tumors \< 5cm, and depth; superficial vs deep.
Exclusion
- Pediatric Patients
- Patients without soft tissue tumors
- Tylenol or oxycodone allergy
Key Trial Info
Start Date :
January 27 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 24 2025
Estimated Enrollment :
116 Patients enrolled
Trial Details
Trial ID
NCT05355597
Start Date
January 27 2021
End Date
March 24 2025
Last Update
April 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Morristown Medical Center
Morristown, New Jersey, United States, 07960